GSK plc


Investor disappointment as vaccines again come up short, despite the Q3 beat

30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."

Pages
65
Language
English
Published on
30/10/24
You may also be interested by these reports :
30/10/24
On the back of the strong performance from Biosimilars, Sandoz again upgraded its full-year outlook. Given that the markets had doubted the firm’s ...

30/10/24
Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for ...

30/10/24
We have raised our 2024 estimates on the back of the management’s vague comments on the positive development for profitability in the Q3. We expect ...

29/10/24
Novartis exceeded expectations with Q3 profitability, and the management upgraded its full-year guidance for the third time this year. Nonetheless, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO